Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.45 |
| ▸ | ITGAV | P06756 | 4/20 | 0.45 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.45 |
| ▸ | ALB | P02768 | 1/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.42 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.41 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.41 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.41 |
| ▸ | CTSG | P08311 | 2/20 | 0.41 |
| ▸ | CD40 | P25942 | 1/20 | 0.40 |
| ▸ | TSLP | Q969D9 | 1/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.39 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.39 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24049373 | 0.95 | ITGB3 (0.45) | KEAP1NFE2L2ITGB3ITGAVCXCR4 | |
| SCHEMBL19365027 | 0.94 | KEAP1 (0.46) | KEAP1NFE2L2ITGB3ITGAVCXCR4 | |
| SCHEMBL16508333 | 0.94 | KEAP1 (0.46) | KEAP1NFE2L2ITGB3ITGAVCXCR4 | |
| SCHEMBL24049285 | 0.94 | KEAP1 (0.46) | KEAP1NFE2L2ITGB3ITGAVCXCR4 | |
| SCHEMBL21906961 | 0.94 | ITGB3 (0.47) | KEAP1NFE2L2ITGB3ITGAVCXCR4 | |
| SCHEMBL21907357 | 0.94 | KEAP1 (0.46) | KEAP1NFE2L2ITGB3ITGAVCXCR4 | |
| SCHEMBL19102256 | 0.94 | ITGB3 (0.47) | KEAP1NFE2L2ITGB3ITGAVCXCR4 | |
| SCHEMBL16508328 | 0.94 | ITGB3 (0.47) | KEAP1NFE2L2ITGB3ITGAVCXCR4 | |
| SCHEMBL21186414 | 0.94 | ITGB3 (0.47) | KEAP1NFE2L2ITGB3ITGAVCXCR4 | |
| SCHEMBL17955327 | 0.94 | ITGB3 (0.46) | KEAP1NFE2L2ITGB3ITGAVCXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210363161-A1 | NITROGEN-CONTAINING MACROCYCLIC CONJUGATES AS RADIOPHARMACEUTICALS | CLARITY PHARMACEUTICALS LTD. (AU) | 2021-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210363161-A1 | NITROGEN-CONTAINING MACROCYCLIC CONJUGATES AS RADIOPHARMACEUTICALS | NCL, NUDC, C3AR1 | KEAP1 1608/4885NFE2L2 1407/4885ITGB3 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.